CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy.

about

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy.

Item

http://www.wikidata.org/entity/Q46588562

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

CRISPR-Cas9 mediated efficient ...... T cells for adoptive therapy.

@en

CRISPR-Cas9 mediated efficient ...... T cells for adoptive therapy.

@nl

type

Item

label

CRISPR-Cas9 mediated efficient ...... T cells for adoptive therapy.

@en

CRISPR-Cas9 mediated efficient ...... T cells for adoptive therapy.

@nl

prefLabel

CRISPR-Cas9 mediated efficient ...... T cells for adoptive therapy.

@en

CRISPR-Cas9 mediated efficient ...... T cells for adoptive therapy.

@nl

P1476

CRISPR-Cas9 mediated efficient ...... T cells for adoptive therapy.

@en

P2093

Baorui Liu

http://www.w3.org/2001/XMLSchema#string

Shu Su

http://www.w3.org/2001/XMLSchema#string

Zhengyun Zou

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

An efficient low cost method for gene transfer to T lymphocytes

Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos.

siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions.

Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies.

Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.

Generation of gene-modified mice via Cas9/RNA-mediated gene targeting.

Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems.

Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects.

P2888

2051-1426-3-s2-p53

P304

P53-P53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2051-1426-3-S2-P53

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 2

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1001406636

http://www.w3.org/2001/XMLSchema#string

P921

CRISPR

P932

4705860

http://www.w3.org/2001/XMLSchema#string